Lung Cancer

Edgardo Santos, MD, discusses the current state of targeted therapies for EGFR- and ALK-positive non–small cell lung cancer, as well as immunotherapy in stage III NSCLC, and management strategies in small cell lung cancer.

Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.

Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.

Sandip P. Patel, MD, discusses novel targets in non–small cell lung cancer.

T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the conditional marketing authorization of sotorasib for the treatment of adult patients with advanced non–small cell lung cancer whose tumors harbor a KRAS G12C mutation and who have progressed after at least 1 prior line of systemic therapy.

Dr Vamsidhar Velcheti evaluates the use of mobocertinib in patients with EGFR exon 20 insertions, and Drs John V. Heymach and Sandip P. Patel discuss the treatment of HER2-mutant NSCLC.

Heather Wakelee, MD, and Stephen Liu, MD, review the treatment of TKI-refractory EGFR-mutant NSCLC.

Nathaniel Ivanick, MD, FCCP, discusses the role of interventional pulmonologists in advanced diagnostics in lung cancer.

Two experts discuss additional studies with antibody-drug conjugates targeting non-small cell lung cancer and the impact of their data on therapeutic options for the disease.

The administration of trilaciclib prior to chemotherapy reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with extensive-stage small cell lung cancer.

Considerations for the FDA approval and practical use of mobocertinib in patients with EGFR exon 20 insertion mutations in NSCLC.

Considerations for the FDA approval and practical use of amivantamab in patients with EGFR exon 20 insertion mutations in non-small cell lung cancer.

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

John F. Lazar, MD, discusses risk stratification for chemotherapy and adjuvant therapy in lung cancer.

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

The FDA granted a fast track designation to the selective AXL inhibitor bemcentinib in combination with a PD-1/PD-L1 agent in the treatment of patients with STK11-altered advanced or metastatic non–small cell lung cancer without actionable mutations.

An increased understanding of the biology of non–small cell lung cancer has led to a significant increase in therapeutic options for patients.

Afshin Dowlati, MD, discusses data from the following presentation: “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study.” (Paz-Ares, ESMO 2021, LBA61)

Ashish Saxena, MD, PhD, discusses a challenging case of a patient with non–small cell lung cancer.

Marjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.

Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.

Mark G. Kris, MD, discusses recent progress in non–small cell lung cancer and small cell lung cancer, efforts being made to address unmet needs in these paradigms, and ongoing research that is generating excitement.

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.